Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

1.

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.

Figg WD, Chau CH, Madan RA, Gulley JL, Gao R, Sissung TM, Spencer S, Beatson M, Aragon-Ching J, Steinberg SM, Dahut WL.

Clin Genitourin Cancer. 2013 Sep;11(3):229-37. doi: 10.1016/j.clgc.2013.04.007. Epub 2013 May 17.

PMID:
23684781
[PubMed - indexed for MEDLINE]
2.

The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.

Liang J, Jiang T, Yao RY, Liu ZM, Lv HY, Qi WW.

Cancer Chemother Pharmacol. 2010 Aug;66(3):493-500. doi: 10.1007/s00280-009-1186-3. Epub 2009 Dec 4.

PMID:
19960344
[PubMed - indexed for MEDLINE]
3.

DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.

Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D.

Clin Lung Cancer. 2009 Mar;10(2):118-23. doi: 10.3816/CLC.2009.n.015.

PMID:
19362955
[PubMed - indexed for MEDLINE]
4.

Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma.

Yin Z, Zhou B, He Q, Li M, Guan P, Li X, Cui Z, Xue X, Su M, Ma R, Bai W, Xia S, Jiang Y, Xu S, Lv Y, Li X.

BMC Cancer. 2009 Dec 15;9:439. doi: 10.1186/1471-2407-9-439.

PMID:
20003463
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.

Chua W, Goldstein D, Lee CK, Dhillon H, Michael M, Mitchell P, Clarke SJ, Iacopetta B.

Br J Cancer. 2009 Sep 15;101(6):998-1004. doi: 10.1038/sj.bjc.6605239. Epub 2009 Aug 11.

PMID:
19672255
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Genetic polymorphisms of ERCC1‑118, XRCC1‑399 and GSTP1‑105 are associated with the clinical outcome of gastric cancer patients receiving oxaliplatin‑based adjuvant chemotherapy.

Liu YP, Ling Y, Qi QF, Zhang YP, Zhang CS, Zhu CT, Wang MH, Pan YD.

Mol Med Rep. 2013 Jun;7(6):1904-11. doi: 10.3892/mmr.2013.1435. Epub 2013 Apr 22.

PMID:
23604281
[PubMed - indexed for MEDLINE]
7.

Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.

Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ.

J Thorac Oncol. 2012 Jun;7(6):973-81. doi: 10.1097/JTO.0b013e31824fe98c.

PMID:
22551904
[PubMed - indexed for MEDLINE]
8.

DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.

Han JY, Yoon KA, Park JH, Lee YJ, Lee GK, Han JH, Yoon SJ, Yun T, Kim HT, Lee JS.

Cancer. 2011 Jul 15;117(14):3201-8. doi: 10.1002/cncr.25863. Epub 2011 Jan 24.

PMID:
21264830
[PubMed - indexed for MEDLINE]
Free Article
9.

Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.

Lu ZM, Luo TH, Nie MM, Fang GE, Ma LY, Xue XC, Wei G, Ke CW, Bi JW.

Tumour Biol. 2014 Apr;35(4):2941-8. doi: 10.1007/s13277-013-1378-7. Epub 2013 Dec 8.

PMID:
24318989
[PubMed - indexed for MEDLINE]
10.

Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.

Joerger M, Burgers SA, Baas P, Smit EF, Haitjema TJ, Bard MP, Doodeman VD, Smits PH, Vincent A, Huitema AD, Beijnen JH, Schellens JH.

Cancer. 2012 May 1;118(9):2466-75. doi: 10.1002/cncr.26562. Epub 2011 Sep 28.

PMID:
22031394
[PubMed - indexed for MEDLINE]
Free Article
11.

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients.

Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH, Rhee J, Park YI, Kim NK.

Br J Cancer. 2011 Mar 29;104(7):1126-34. doi: 10.1038/bjc.2011.24. Epub 2011 Mar 1.

PMID:
21364592
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer.

Heidenreich A, Rawal SK, Szkarlat K, Bogdanova N, Dirix L, Stenzl A, Welslau M, Wang G, Dawkins F, de Boer CJ, Schrijvers D.

Ann Oncol. 2013 Feb;24(2):329-36. doi: 10.1093/annonc/mds505. Epub 2012 Oct 26.

PMID:
23104724
[PubMed - indexed for MEDLINE]
Free Article
13.

Different relation between ERCC1 overexpression and treatment outcomes of two platinum agents in advanced biliary tract adenocarcinoma patients.

Hwang IG, Jang JS, Do JH, Kang JH, Lee GW, Oh SY, Kwon HC, Jun HJ, Lim HY, Lee S, Chi KC, Lee SJ.

Cancer Chemother Pharmacol. 2011 Oct;68(4):935-44. doi: 10.1007/s00280-011-1558-3. Epub 2011 Feb 5.

PMID:
21298384
[PubMed - indexed for MEDLINE]
14.

The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.

Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN.

Gynecol Oncol. 2013 Aug;130(2):377-82. doi: 10.1016/j.ygyno.2013.04.054. Epub 2013 Apr 28.

PMID:
23632208
[PubMed - indexed for MEDLINE]
15.

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ.

J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26.

PMID:
22454414
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.

Michaelson MD, Oudard S, Ou YC, Sengeløv L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullèn A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I.

J Clin Oncol. 2014 Jan 10;32(2):76-82. doi: 10.1200/JCO.2012.48.5268. Epub 2013 Dec 9.

PMID:
24323035
[PubMed - indexed for MEDLINE]
17.

Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.

Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA; Gynecologic Oncology Group Phase III Trial.

J Clin Oncol. 2008 Jul 20;26(21):3598-606. doi: 10.1200/JCO.2008.16.1323.

PMID:
18640939
[PubMed - indexed for MEDLINE]
18.

Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

Simon GR, Schell MJ, Begum M, Kim J, Chiappori A, Haura E, Antonia S, Bepler G.

Cancer. 2012 May 1;118(9):2525-31. doi: 10.1002/cncr.26522. Epub 2011 Oct 25.

PMID:
22028294
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).

Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ; Alliance for Clinical Trials in Oncology.

Cancer. 2013 Oct 15;119(20):3636-43. doi: 10.1002/cncr.28285. Epub 2013 Jul 31.

PMID:
23913744
[PubMed - indexed for MEDLINE]
20.

Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.

Gil-Bazo I, Arévalo E, Castillo A, Zudaire ME, Carranza OE, Fusco JP, Castañón E, Collado-Gómez V, López I, Gil-Aldea I.

Clin Genitourin Cancer. 2013 Jun;11(2):78-84. doi: 10.1016/j.clgc.2012.11.003. Epub 2012 Dec 21.

PMID:
23260990
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk